Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36.36 USD | +1.54% | -2.26% | +31.93% |
May. 24 | Ptc Therapeutics Insider Sold Shares Worth $764,800, According to a Recent SEC Filing | MT |
May. 21 | Goldman Sachs Adjusts PTC Therapeutics Price Target to $32 From $18, Maintains Sell Rating | MT |
Evolution of the average Target Price on PTC Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering PTC Therapeutics, Inc.
Goldman Sachs | |
Raymond James | |
Morgan Stanley | |
TD Cowen | |
RBC Capital Markets | |
Cantor Fitzgerald | |
Barclays | |
Citigroup | |
Truist Securities | |
JPMorgan Chase | |
UBS | |
Credit Suisse | |
BofA Securities | |
SVB Securities LLC | |
Jefferies & Co. |
EPS Revisions
- Stock Market
- Equities
- PTCT Stock
- Consensus PTC Therapeutics, Inc.